Mineralys Therapeutics, Inc. MLYS Deferred offering costs
Deferred offering costs at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredOfferingCosts.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s deferred offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s deferred offering costs?
- Mineralys Therapeutics, Inc. (MLYS) reported deferred offering costs of $200K in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s deferred offering costs changed year-over-year?
- Mineralys Therapeutics, Inc.'s deferred offering costs decreased by 33.3% year-over-year, from $300K to $200K.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s deferred offering costs?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s deferred offering costs has grown at a -50.0% compound annual growth rate (CAGR), from $1.6M to $200K.
- What does deferred offering costs mean?
- These are capitalized costs directly attributable to a planned or ongoing equity or debt offering that have not yet been recognized in the income statement. Once the offering is completed, these costs are typically reclassified as a reduction of the proceeds from the offering.